| Essential insights to advance vaccine development and delivery Vaccine Insights is an online, open-access, peer-reviewed journal covering the latest advances in vaccine R&D, formulation, regulation, immunology, manufacturing, QA/QC and pandemic preparedness. Guided by an expert advisory board, the journal brings together insights on emerging vaccine technologies, next-generation platforms, and transformative approaches reshaping how vaccines are discovered, developed and delivered. Sign-up for free to gain unlimited access to our extensive collection of articles, webinars, podcasts, news, and interviews, and remain at the forefront of vaccine innovation. |  |
June 2026
Volume 5 Issue 5
In this issue, we find out what a worst-case pandemic would actually look like, discover why cold chain reliability depends as much on technician behaviour as on equipment, and learn why immunobridging requires more than a statistical bridge to support vaccine licensure.
"No pandemic waits for us to catch up." – Michael Osterholm, Director, Center for Infectious Disease Research and Policy, University of Minnesota, USA
"Immunobridging is only as strong as the framework surrounding it." – Marion F Gruber, Vice President, Public Health and Regulatory Affairs, IAVI
Upcoming webinars
Converting to animal-origin-free peptones with 2- to 5-fold improved bacterial growth
Elizabeth O'Hanlon, Chris Titensor
28 July
in 10
Days
Replacing in vivo adventitious agent tests with NGS: from regulatory permission to routine practice
C Swofford, PhD, A S. Khan, PhD, S Ayama, PhD
19 August
in 32
Days
Latest Articles
Cut upstream veterinary vaccine manufacturing costs by up to 89% per dose
Alex Chatel
14 July
Industry Insights: A new Ebola emergency, a Lassa fever first, and the race to close the neglected pathogen gap
Ashling Cannon
9 July
A return to normalcy: vaccine makers assert patents to protect proprietary technologies
Kevin E Noonan
2 July
The next pandemic will not wait: universal vaccines, pandemic preparedness, and the integrity of vaccine policy
Michael Osterholm
26 June
From one target to many: how high‑plex ddPCR technology is changing CGT from development to analytics
Christian Overgaard
24 June
Muscle dilemma: the great debate over myocyte expression in mRNA vaccination
Arnab Rudra
12 June
Designing for the technician: behavioral drivers of an effective cold chain maintenance system
Sohail Agha, Wendy Prosser, Ifeanyi Nsofor
11 June
Immunobridging as a regulatory strategy: science, standardization, and global equity
Marion F Gruber
9 June
Adjuvanted vaccines as tools to enhance immunity and support healthy aging in older adults
S De Gussem , B Jacobs, A Alhatemi et al.
8 June
Latest channel content
A return to normalcy: vaccine makers assert patents to protect proprietary technologies
Kevin E Noonan
2 July
The next pandemic will not wait: universal vaccines, pandemic preparedness, and the integrity of vaccine policy
Michael Osterholm
26 June
Muscle dilemma: the great debate over myocyte expression in mRNA vaccination
Arnab Rudra
12 June
A return to normalcy: vaccine makers assert patents to protect proprietary technologies
Kevin E Noonan
2 July
Immunobridging as a regulatory strategy: science, standardization, and global equity
Marion F Gruber
9 June
Industry Insights: A malaria proof point and the world’s first pertussis challenge trial: a post-pandemic vaccine landscape
Ashling Cannon
8 June
The next pandemic will not wait: universal vaccines, pandemic preparedness, and the integrity of vaccine policy
Michael Osterholm
26 June
Designing for the technician: behavioral drivers of an effective cold chain maintenance system
Sohail Agha, Wendy Prosser, Ifeanyi Nsofor
11 June
Immunobridging as a regulatory strategy: science, standardization, and global equity
Marion F Gruber
9 June
A return to normalcy: vaccine makers assert patents to protect proprietary technologies
Kevin E Noonan
2 July
Industry Insights: A malaria proof point and the world’s first pertussis challenge trial: a post-pandemic vaccine landscape
Ashling Cannon
8 June
Designing the next generation of vaccine adjuvants
D O’Hagan, E Lavelle, A Joffe et al.
21 May
Cut upstream veterinary vaccine manufacturing costs by up to 89% per dose
Alex Chatel
14 July
Designing for the technician: behavioral drivers of an effective cold chain maintenance system
Sohail Agha, Wendy Prosser, Ifeanyi Nsofor
11 June
Industry Insights: A malaria proof point and the world’s first pertussis challenge trial: a post-pandemic vaccine landscape
Ashling Cannon
8 June
Industry Insights: A malaria proof point and the world’s first pertussis challenge trial: a post-pandemic vaccine landscape
Ashling Cannon
8 June
Safety Assessment of Vaccines against Priority Pathogens: the CEPI Safety Platform for Emergency Vaccines (SPEAC) Project, 2019–2026
E C Farnon, C Cassard, S Black et al.
2 June
Continuous vaccine manufacturing: challenges and technological solutions
Ravi Ganapathy
14 May
A return to normalcy: vaccine makers assert patents to protect proprietary technologies
Kevin E Noonan
2 July
Immunobridging as a regulatory strategy: science, standardization, and global equity
Marion F Gruber
9 June
Industry Insights: A malaria proof point and the world’s first pertussis challenge trial: a post-pandemic vaccine landscape
Ashling Cannon
8 June
Industry Insights: A malaria proof point and the world’s first pertussis challenge trial: a post-pandemic vaccine landscape
Ashling Cannon
8 June
Targeting the full neoantigen landscape: DNA vaccine design and personalization in cancer immunotherapy
Jian Yan
19 May
Measles, Marburg, and mounting policy discord: a vaccine landscape under pressure
Ashling Cannon
7 May
| Your content marketing partner for life sciences BioInsights is a global content marketing and demand generation partner for the life sciences industry. With a community of 60,000+ registered users spanning biotech, pharma, academia, and solution providers, we help you reach the people that matter, through tailored content strategies, high-impact lead generation, and expert-led publishing across every major biopharma modality. Explore the media kit to find out more about our offering or contact us to see how we can support your marketing efforts. View our media kit |  |
| Our journals Our portfolio of four open access journals provides trusted insight across the advanced therapies landscape. Cell & Gene Therapy Insights, Bioconjugate Insights, Vaccine Insights, and Nucleic Acids Insights deliver expert commentary, original research, and practical guidance that help researchers, developers, and manufacturers stay aligned with the rapidly evolving needs of modern biomedicine. Each journal focuses on translating innovation into real-world impact, giving readers clear, actionable knowledge that supports progress from discovery through to clinical and commercial success. Want to keep up with the latest journal content and upcoming webinars? |  View |  View |  View |  View |
FAQs |
| Get in touch Ready to connect? Our team is here to answer questions, explore ideas, and help you get the most from your partnership with BioInsights. Reach out and let us know how we can support you. Contact us |
| Bioconjugate Insights | Cell & Gene Therapy Insights | Nucleic Acid Insights | Vaccine Insights |